Department of Biochemistry and Cell Biology, School of Medicine, and Cell & Matrix Research Institute, Kyungpook National University, Daegu 41944, Republic of Korea.
Department of Pathology, All India Institute of Medical Sciences, New Delhi-110029, India.
Nanotheranostics. 2020 Jan 15;4(2):57-70. doi: 10.7150/ntno.39804. eCollection 2020.
In order to improve clinical outcomes for novel drug delivery systems, distinct optimization of size, shape, multifunctionality, and site-specificity are of utmost importance. In this study, we designed various multivalent elastin-like polypeptide (ELP)-based tumor-targeting polymers in which multiple copies of IL-4 receptor (IL-4R)-targeting ligand (AP1 peptide) were periodically incorporated into the ELP polymer backbone to enhance the affinity and avidity towards tumor cells expressing high levels of IL-4R. Several ELPs with different molecular sizes and structures ranging from unimer to micelle-forming polymers were evaluated for their tumor accumulation as well as bio-distribution patterns. Different percentages of cell binding and uptake were detected corresponding to polymer size, number of targeting peptides, or unimer versus micelle structure. As compared to low molecular weight polypeptides, high molecular weight AP1-ELP showed superior binding activity with faster entry and efficient processing in the IL-4R-dependent endocytic pathway. In addition, studies revealed that the high molecular weight micelle-forming AP1-ELPs (A86 and A100) displayed better tumor penetration and extensive retention in tumor tissue along with reduced non-specific accumulation in vital organs, when compared to low molecular weight non-micelle forming AP1-ELPs. It is suggested that the superior binding activities shown by A86 and A100 may depend on the multiple presentation of ligands upon transition to a micelle-like structure rather than a larger molecular weight. Thus, this study has significance in elucidating the different patterns underlying unimer and micelle-forming ELP-mediated tumor targeting as well as the biodistribution.
为了改善新型药物传递系统的临床效果,大小、形状、多功能性和靶向特异性的显著优化至关重要。在这项研究中,我们设计了各种多价弹性蛋白样多肽(ELP)为基础的肿瘤靶向聚合物,其中多个拷贝的白细胞介素-4 受体(IL-4R)靶向配体(AP1 肽)周期性地被整合到 ELP 聚合物主链中,以增强对表达高水平 IL-4R 的肿瘤细胞的亲和力和效价。几种具有不同分子大小和结构的 ELP,从单体到胶束形成聚合物,都被评估了它们的肿瘤积累和生物分布模式。不同百分比的细胞结合和摄取与聚合物大小、靶向肽数量或单体与胶束结构有关。与低分子量多肽相比,高分子量 AP1-ELP 与 IL-4R 依赖性内吞途径的更快进入和更有效的处理相关,表现出更好的结合活性。此外,研究表明,与低分子量非胶束形成的 AP1-ELPs(A86 和 A100)相比,高分子量胶束形成的 AP1-ELPs(A86 和 A100)在肿瘤组织中具有更好的肿瘤穿透性和广泛的保留性,同时在重要器官中的非特异性积累减少。这表明,A86 和 A100 表现出的优越结合活性可能依赖于配体在向胶束样结构转变时的多次呈现,而不是分子量的增加。因此,这项研究对于阐明单体和胶束形成的 ELP 介导的肿瘤靶向以及生物分布的不同模式具有重要意义。